Related Experiment Videos
Inhibition of HIV-1 replication by an anti-tat hammerhead ribozyme
W H Jackson1, H Moscoso, J F Nechtman
1Department of Biology and Geology, University of South Carolina, Aiken, South Carolina, 29801, USA.
Biochemical and Biophysical Research Communications
|May 16, 1998
Summary
This study demonstrates that an anti-tat ribozyme delivered via a retroviral vector can effectively inhibit HIV-1 replication in CD4(+) cells, offering a potential new strategy for AIDS treatment.
Area of Science:
- Molecular Biology
- Virology
- Gene Therapy
Background:
- Human Immunodeficiency Virus type 1 (HIV-1) replication is regulated by the viral Tat protein.
- Developing strategies to inhibit Tat is crucial for controlling HIV-1 infection and Acquired Immunodeficiency Syndrome (AIDS).
Purpose of the Study:
- To investigate the efficacy of inhibiting HIV-1 replication using an anti-tat hammerhead ribozyme delivered by a retroviral vector.
- To assess the protective potential of this gene therapy approach in relevant cell types.
Main Methods:
- Construction of a retroviral vector expressing an anti-tat hammerhead ribozyme.
- Testing the vector's efficiency in reducing Tat activity in COS-7 cells using CAT assays.
- Evaluating the vector's ability to confer resistance to HIV-1 challenge in CD4(+) peripheral blood lymphocytes (PBLs) via pseudotyped retroviral particles.
Main Results:
- The anti-tat ribozyme vector reduced Tat activity by 85-95% in engineered cells.
- Transduced CD4(+) PBLs demonstrated resistance to HIV-1 infection for up to 20 days, evidenced by reduced cell death and reverse transcriptase activity.
- Successful delivery and protective function of the ribozyme were confirmed.
Conclusions:
- A pseudotyped retroviral vector can effectively deliver a protective anti-tat ribozyme to CD4(+) cells.
- This approach shows proof of principle for controlling HIV-1 replication.
- Targeted delivery of ribozymes represents a promising gene therapy strategy against HIV-1/AIDS.